ChinaDaily Briefs

Daily Brief China: Guotai Junan Securities , China National Building Material, Fosun Tourism, Singamas Container Holdings, Contemporary Amperex Technology (CATL), Sinopharm Group Co Ltd H and more

In today’s briefing:

  • Guotai Junan/Haitong Sec Merger: The Many Index Flows Around the Corner
  • China National Building Material (3323 HK): H Share Buyback Vote on 19 February
  • Merger Arb Mondays (27 Jan) – Fosun Tourism, Get Nice, Lifestyle China, Canvest, Japfa, SLB
  • CNBM (3323 HK): This Is An “Avoid” Ahead Of 19th Feb H-Class Shareholder Vote
  • Singamas (716 HK): Further Positive Indications from CIMC Profit Alert
  • China National Building Material (3323 HK): Publication of Buyback Offer Document
  • ECM Weekly (27th Jan 2025) – CATL, HDB Financial, Dr Agarwal’s, Eco-Shop, Vikran, Sanil, Timee
  • Sinopharm Group Co Ltd (1099.HK) – Performance May Continue to Miss Expectations


Guotai Junan/Haitong Sec Merger: The Many Index Flows Around the Corner

By Brian Freitas


China National Building Material (3323 HK): H Share Buyback Vote on 19 February

By Arun George

  • The IFA opines that the China National Building Material (3323 HK) share buyback, which will acquire a maximum of 841.7 million H Shares at HK$4.03, is fair and reasonable.
  • The share buyback seems designed to enable the CNBM parent company to bypass the creeper rule and squeeze the shorts. 
  • The fortuitous material derating of peers has helped make the buyback attractive. Therefore, the votes should pass, and the minimum acceptance condition should be met. 

Merger Arb Mondays (27 Jan) – Fosun Tourism, Get Nice, Lifestyle China, Canvest, Japfa, SLB

By Arun George


CNBM (3323 HK): This Is An “Avoid” Ahead Of 19th Feb H-Class Shareholder Vote

By David Blennerhassett

  • On the 6th December, China National Building Material (3323 HK) (CNBM), a leading PRC building materials company, offered to buy back 841,749,304 H-shares at HK$4.03/share, a 15.1% premium to undisturbed.
  • The thrust of the buyback lifts the stake of CNBM’s parent – the CNBM Parent Concert Group – to 50.01% of total shares from 45.02% currently, necessitating a whitewash waiver.
  • Pre-Cons were satisfied on the 24th Jan. The independent H-class shareholders vote for the waiver is on the 19th Feb. Minimum pro-ration is 19.24%. Implied back-end price is well down. 

Singamas (716 HK): Further Positive Indications from CIMC Profit Alert

By Osbert Tang, CFA

  • China International Marine Cntnrs Gp (2039 HK)‘s positive profit alert suggested a very solid performance for Singamas Container Holdings (716 HK) in 4Q24. 
  • Annualising Singamas’ 1H24 earnings for the full year will mean a 78% profit surge in 2H24, but this is still conservative – CIMC’s 2H24 profit leaped 93x YoY.
  • Trading on 6x PER, versus CIMC’s 10.3x, the stock is cheap. Net cash equals 86% of market capitalisation, potentially providing a yield higher than the 8.8% currently projected.

China National Building Material (3323 HK): Publication of Buyback Offer Document

By Osbert Tang, CFA

  • China National Building Material (3323 HK) published the H-share offer document and if everything is smooth, the payment will be made on 14 Mar 2025. 
  • Its two subsidiaries forecast poor profit/losses for FY24, suggesting a tough operating environment. The buyback valuation remains attractive relative to peer multiples.
  • For non-holders, at the current price of HK$3.59, we do not think the safety margin is good enough, assuming that most existing shareholders will accept and tender.

ECM Weekly (27th Jan 2025) – CATL, HDB Financial, Dr Agarwal’s, Eco-Shop, Vikran, Sanil, Timee

By Sumeet Singh


Sinopharm Group Co Ltd (1099.HK) – Performance May Continue to Miss Expectations

By Xinyao (Criss) Wang

  • Due to disappointing performance in 24Q1-Q3, both revenue and net profit attributable to the parent company in 2024 could face negative growth, but 2025 is expected to have positive growth.
  • As pharmaceutical distribution business can just maintain stable but medical device distribution business and retail pharmacies cannot contribute high growth, the overall performance of Sinopharm has lost growth momentum.
  • Due to longer payment cycles from hospitals and its business characteristics, Sinopharm is facing significant demands for working capital. Insufficient cash flow makes it difficult to increase the dividend rate.  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars